Tom Daniel, M.D., is a member of the board of directors at VIR. As President, Research & Early Development at Celgene Corporation over the past decade, he led the diversification and expansion of a robust internal pipeline of product candidates in oncology and immune-inflammatory diseases, amplified by construction of an extensive collaborative network of partner companies. New drug submissions, and advancement of multiple candidates through proof of concept have ensued. Dr. Daniel currently serves as director at JUNO Therapeutics, Zafgen Corporation, Vividion, and Magenta Therapeutics, and on scientific advisory boards for aTyr Pharma and Vanderbilt University Medical Center.
He previously served as chief scientific officer and director of Ambrx, as vice president and site head at Amgen Corporation, and as senior vice president, research at Immunex Corporation. Formerly Hakim Professor of Medicine and Cell Biology at Vanderbilt University, Dr. Daniel practiced nephrology, led research programs in the Vanderbilt-Ingram Cancer Center, and co-directed the M.D./Ph.D. program. He trained in internal medicine at Massachusetts General Hospital, in molecular genetics with Michael Brown and Joseph Goldstein, and a was recipient of NIH and HHMI research funding for over 20 years.